Back to top
more

Cytosorbents (CTSO)

(Delayed Data from NSDQ)

$0.90 USD

0.90
53,514

+0.02 (2.28%)

Updated May 31, 2024 04:00 PM ET

After-Market: $0.90 0.00 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Cytosorbents Corporation [CTSO]

Reports for Purchase

Showing records 41 - 60 ( 183 total )

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 41

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CTSO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 42

09/01/2021

Company Report

Pages: 4

BUY: COVID ARDS (ECMO) Trial Shows Efficacy

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 43

09/01/2021

Company Report

Pages: 4

BUY: COVID ARDS (ECMO) Trial Shows Efficacy

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 44

08/04/2021

Company Report

Pages: 6

Continued Topline Growth; STAR-T on U.S. Ticagrelor Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 45

07/06/2021

Company Report

Pages: 4

BUY: CytoSorbents STAR Shines Bright

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 46

05/06/2021

Company Report

Pages: 4

BUY: First-Quarter Results are Ok

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 47

05/05/2021

Company Report

Pages: 6

COVID Revenues Likely to Rebound; Starting Multiple Clinical Studies; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 48

04/20/2021

Company Report

Pages: 4

BUY: A Star is Born - Pivotal P3 Trial Begins

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 49

03/12/2021

Company Report

Pages: 4

BUY: Another Strong Quarter

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 50

03/10/2021

Company Report

Pages: 7

Record Year Boosted by COVID Sales; Continued Growth Expected in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 51

01/19/2021

Company Report

Pages: 4

BUY: The Good Doctor: Cytosorb Approved in Korea

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 52

01/13/2021

Daily Note

Pages: 3

A Strong Finish to 2020; We Expect Continued Growth in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LEE S

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 53

01/12/2021

Company Report

Pages: 4

BUY: Solids Revenues in 2020

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 54

12/02/2020

Company Report

Pages: 5

BUY: How did CytoSorb Perform in 50 COVID Patients?

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 55

11/05/2020

Company Report

Pages: 7

BUY: Reports a Strong Quarter, Partly Driven by COVID, $88 Million in Cash

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 56

11/05/2020

Company Report

Pages: 6

Continued Sales Growth; Significant Clinical Expansion in 2021; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 57

10/14/2020

Company Report

Pages: 7

BUY: EU Approval for the PerLife Ex System, which uses PerSorb Cartridge for Solid Organ Transplant

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 58

09/16/2020

Company Report

Pages: 7

BUY: Enrolling Patients for COVID

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 59

08/12/2020

Company Report

Pages: 7

BUY: Record Revenues - This is Just the Beginning

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Cytosorbents Corporation

Industry: Medical - Products

Record: 60

08/06/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party